Dr. Brad Brimhall discusses the Protecting Access to Medicare Act of 2014 (PAMA), its likely effect on laboratories, and the long term effects in regard to emerging value-based purchasing payment systems such as MACRA and VBP. Dr. Brimhall covers the importance of having an accurate lab cost analysis, defines cost accounting terms, and shares a cost comparison of top laboratory tests and expected PAMA reimbursements.
![]()
Following the webinar, you will be able to:
Download the presentation slides About the speaker: Dr. Brimhall is a Clinical Professor of Pathology, Staff Pathologist, and Medical Director of Integrated Healthcare Analytics and Bioinformatics in the Department of Pathology, University of Texas Health Science Center in San Antonio. He is an expert in medical analytics and data warehousing. His primary interest is in integrated medical analytics, leveraging data warehousing, big data, statistics, etc. to merge clinical diagnostic data from pathology, laboratory medicine, and other clinical areas with detailed operational and financial data to make the most cost-effective and patient-focused use of diagnostic information. Dr. Brimhall received his medical degree from Stanford Medical School. He completed his residency in Anatomic and Clinical Pathology at Brigham and Women’s Hospital and Harvard Medical School and also holds a master’s degree (MPH) in Healthcare Policy and Management from the Harvard School of Public Health. In addition, Dr. Brimhall is board certified in Anatomic and Clinical Pathology as well as Clinical Informatics. Comments are closed.
|
Archives
November 2020
Categories
|